The management of Leishmania donova ni (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug-unresponsiveness, leading to increasing treatment ...

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Researchers analysed over 6,000 serum samples from blood tests ordered by GPs which had been tested in eight hospital laboratories around the country for the presence of Hepatitis B surface antigen ...

A study to determine the extent of such blood-borne infections in the community also found that the prevalence of Hepatitis B and HIV was 'significantly higher' in the Cork region ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

BJT-778 targets the hepatitis B virus surface antigen. Credit: Orawan Pattarawimonchai/Shutterstock. The US Food and Drug Administration (FDA) has granted ...

About Brelovitug (also known as BJT-778) Brelovitug is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B ...